BRPI0909119A2 - vetores recombinantes do rinovírus - Google Patents
vetores recombinantes do rinovírusInfo
- Publication number
- BRPI0909119A2 BRPI0909119A2 BRPI0909119A BRPI0909119A BRPI0909119A2 BR PI0909119 A2 BRPI0909119 A2 BR PI0909119A2 BR PI0909119 A BRPI0909119 A BR PI0909119A BR PI0909119 A BRPI0909119 A BR PI0909119A BR PI0909119 A2 BRPI0909119 A2 BR PI0909119A2
- Authority
- BR
- Brazil
- Prior art keywords
- rhinovirus vectors
- recombinant rhinovirus
- recombinant
- vectors
- rhinovirus
- Prior art date
Links
- 241000709661 Enterovirus Species 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32741—Use of virus, viral particle or viral elements as a vector
- C12N2770/32743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7203608P | 2008-03-27 | 2008-03-27 | |
| PCT/US2009/001941 WO2009120380A2 (en) | 2008-03-27 | 2009-03-27 | Recombinant rhinovirus vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0909119A2 true BRPI0909119A2 (pt) | 2017-06-13 |
Family
ID=41114548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0909119A BRPI0909119A2 (pt) | 2008-03-27 | 2009-03-27 | vetores recombinantes do rinovírus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110091501A1 (pt) |
| EP (1) | EP2257308A4 (pt) |
| JP (1) | JP2011517408A (pt) |
| KR (1) | KR20110005826A (pt) |
| CN (1) | CN102089003A (pt) |
| AU (1) | AU2009229165A1 (pt) |
| BR (1) | BRPI0909119A2 (pt) |
| CA (1) | CA2718731A1 (pt) |
| IL (1) | IL208321A0 (pt) |
| MX (1) | MX2010010457A (pt) |
| WO (1) | WO2009120380A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069483A4 (en) * | 2006-09-29 | 2010-10-27 | Sanofi Pasteur Biologics Co | RECOMBINANT RHINOVIRAL VECTORS |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| WO2013157648A1 (ja) * | 2012-04-19 | 2013-10-24 | 国立大学法人九州大学 | 医薬組成物 |
| EP2765137A1 (en) * | 2013-02-07 | 2014-08-13 | Sanofi Pasteur | Induction of cross-reactive cellular response against rhinovirus antigens |
| WO2016042059A1 (en) * | 2014-09-18 | 2016-03-24 | Glaxosmithkline Biologicals S.A. | Vaccine |
| PL3095866T3 (pl) | 2015-05-20 | 2019-09-30 | Secarna Pharmaceuticals Gmbh & Co. Kg | Środek do profilaktyki i terapii infekcji wirusowych |
| EP3103474A1 (en) * | 2015-06-12 | 2016-12-14 | Institut Pasteur | Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses |
| EP3307311A4 (en) * | 2015-06-15 | 2019-02-13 | Emory University | MULTIVALENT ENTOVIRUS VACCINE COMPOSITIONS AND RELATED USES |
| US10428116B2 (en) * | 2016-04-22 | 2019-10-01 | Wisconsin Alumni Research Foundation | Rhinovirus C immunogenic peptides |
| CN109694401A (zh) * | 2017-10-20 | 2019-04-30 | 金协国际实业有限公司 | 败血性巴氏杆菌毒素重组蛋白、其类病毒颗粒及其应用 |
| CN115991744A (zh) * | 2021-07-26 | 2023-04-21 | 北京万泰生物药业股份有限公司 | 人鼻病毒的通用亲和表位多肽、抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714374A (en) * | 1990-09-12 | 1998-02-03 | Rutgers University | Chimeric rhinoviruses |
| US5541100A (en) * | 1990-09-12 | 1996-07-30 | Rutgers University | Chimeric rhinoviruses |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| EP1256803A1 (en) * | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Methods for the identification of antiviral compounds |
| CN1551782A (zh) * | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
| US20060088549A1 (en) * | 2004-07-08 | 2006-04-27 | Arnold Gail F | Chimeric virus vaccine |
| US8420102B2 (en) * | 2006-03-07 | 2013-04-16 | Vaxinnate Corporation | Compositions that include hemagglutinin |
| EP1984022A2 (en) * | 2006-01-17 | 2008-10-29 | CREATOGEN Laboratories GmbH | Influenza vaccine |
| EP2069483A4 (en) * | 2006-09-29 | 2010-10-27 | Sanofi Pasteur Biologics Co | RECOMBINANT RHINOVIRAL VECTORS |
| US8652486B2 (en) * | 2006-09-29 | 2014-02-18 | Sanofi Pasteur Biologics, Llc | Neutralizing immunogen (NimIV) of rhinovirus and its use for vaccine applications |
| EP2121010A4 (en) * | 2007-01-31 | 2011-02-16 | Sanofi Pasteur Biologics Co | RECOMBINANT BICISTRONIC FLAVIRUS VECTORS |
| EP2240199A4 (en) * | 2008-02-09 | 2012-10-03 | Sanofi Pasteur Biologics Llc | INFLUENZA VACCINES |
| JP5779352B2 (ja) * | 2008-03-14 | 2015-09-16 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 複製欠損フラビウイルスワクチンおよびワクチンベクター |
-
2009
- 2009-03-27 EP EP09726224A patent/EP2257308A4/en not_active Withdrawn
- 2009-03-27 MX MX2010010457A patent/MX2010010457A/es not_active Application Discontinuation
- 2009-03-27 US US12/934,095 patent/US20110091501A1/en not_active Abandoned
- 2009-03-27 CA CA2718731A patent/CA2718731A1/en not_active Abandoned
- 2009-03-27 JP JP2011501841A patent/JP2011517408A/ja active Pending
- 2009-03-27 CN CN2009801201791A patent/CN102089003A/zh active Pending
- 2009-03-27 WO PCT/US2009/001941 patent/WO2009120380A2/en not_active Ceased
- 2009-03-27 AU AU2009229165A patent/AU2009229165A1/en not_active Abandoned
- 2009-03-27 BR BRPI0909119A patent/BRPI0909119A2/pt not_active IP Right Cessation
- 2009-03-27 KR KR1020107024112A patent/KR20110005826A/ko not_active Withdrawn
-
2010
- 2010-09-21 IL IL208321A patent/IL208321A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2257308A4 (en) | 2012-06-27 |
| JP2011517408A (ja) | 2011-06-09 |
| WO2009120380A3 (en) | 2009-12-30 |
| CN102089003A (zh) | 2011-06-08 |
| KR20110005826A (ko) | 2011-01-19 |
| WO2009120380A2 (en) | 2009-10-01 |
| AU2009229165A1 (en) | 2009-10-01 |
| IL208321A0 (en) | 2010-12-30 |
| CA2718731A1 (en) | 2009-10-01 |
| US20110091501A1 (en) | 2011-04-21 |
| EP2257308A2 (en) | 2010-12-08 |
| MX2010010457A (es) | 2010-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301082I2 (nl) | luspatercept | |
| BRPI0909119A2 (pt) | vetores recombinantes do rinovírus | |
| EP2296708A4 (en) | POLYMER CARRIER | |
| EP2276499A4 (en) | ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED | |
| EP2303378A4 (en) | INTERFACE | |
| PT2813570T (pt) | Resumo | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| PT3045471T (pt) | Resumo | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| EP2337157A4 (en) | CONNECTOR | |
| DK2300238T3 (da) | Skyggebillede-sikkerhedstræk | |
| BRPI0908382A2 (pt) | Material reforçado | |
| BRPI0907522A2 (pt) | biarlamidas | |
| BRPI0915562A2 (pt) | tamis melhorado | |
| BRPI1010661A2 (pt) | peptídeo | |
| BRPI0915442A2 (pt) | tamis melhorado | |
| BRPI0909634A2 (pt) | 2-aminoquinolinas | |
| EP2318537A4 (en) | OPTIMIZED PROMOTER SEQUENCE | |
| BRPI0909637A2 (pt) | 2-aminoquinolinas | |
| BRPI0907863A2 (pt) | pirrolopirimidinacarboxamidas | |
| AT507449A3 (de) | Dämmstoffbefestiger | |
| IT1395137B1 (it) | Nuovi peptidi antipatogeni | |
| EP2252310A4 (en) | HETEROCYCLIC PEPTIDE KETOAMIDE | |
| EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
| EP2370100A4 (en) | PEPTIDE AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |